Stifel Nicolaus started coverage on shares of Rapport Therapeutics (NASDAQ:RAPP – Free Report) in a report released on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $35.00 target price on the stock.
Rapport Therapeutics Trading Down 1.7 %
Shares of NASDAQ:RAPP opened at $25.01 on Tuesday. Rapport Therapeutics has a fifty-two week low of $18.00 and a fifty-two week high of $27.11.
Further Reading
- Five stocks we like better than Rapport Therapeutics
- What Are Trending Stocks? Trending Stocks Explained
- RXO Shares Surge Following New Acquisition Deal
- Stock Dividend Cuts Happen Are You Ready?
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- What are earnings reports?
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
